课题基金 / 基金详情

Role of Interferon Regulatory Factor 9 (IRF9) in Heart Failure Progression and as a Novel Biomarker of Human Heart Failure through Exosomal Signaling

Role of Interferon Regulatory Factor 9 (IRF9) in Heart Failure Progression and as a Novel Biomarker of Human Heart Failure through Exosomal Signaling
干扰素调节因子 9 (IRF9) 在心力衰竭进展中的作用以及通过外泌体信号传导作为人类心力衰竭的新型生物标志物
批准号：
229253
负责人：
Liu Peter P
金额：
$16.39万
依托单位：
University Health Network (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2011
资助国家：
加拿大
项目状态：
已结题
起止时间：
2011-03-01 至 2014-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=229253&lang=en
关键词：
Cardiovascular Remodeling Disease Biomarker Exosomes Gene Targeted Mouse Models Heart Failure Hypertrophy Innate Immunity Interferon Regulatory Factor Proteomics Transcription Factor

项目摘要

项目成果

Liu Peter P的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Heart failure, or progressive weakness of heart muscle, is a major public health problem in both China and Canada, affecting 1 in 5 of Canadian population. Progressive changes in heart structure and function after injury such as heart attack or high bloo
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The COVID-R3ICSAB Study: COVID-19 Wide Impact: Research on the Risk and Resilience In Special Communities of Chinese, South Asian and Black Populations
COVID-19 Variant Supplement - Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial
COVID-19 Vaccine-Induced Inflammatory Heart Disease Prevalence Registry and Cohort Study (COVID-VIHPR)
Improving Outcomes in Individuals with COVID-19 with Renin-Angiotensin System Inhibition: The COVID-RASi Trial
海外基金